Published Date: 29 Oct 2025
Women living in parts of the United States with lower air quality, especially neighborhoods with heavy emissions from motor vehicles, are more likely to develop breast cancer, according to a multiyear analysis involving more ...
Read Full NewsPhase 3b study revealed Itvisma's safety and efficacy in treating spinal muscular atrophy, showing modest motor function improvements in patients previously on other therapies.
FDA Approves Nerandomilast (Jascayd) Tablets for Progressive Pulmonary Fibrosis
Renal Transplantation May Lower Sleep Disorder Risk Versus Dialysis
BMI, Inflammatory Bowel Disease Both Show Causal Effect on HS Development
The HCPFive: Top News for Healthcare Providers from the Week of 12/14
1.
Cancer Patients Who Completed Medication Survey Received More Help From Pharmacists
2.
Fitness levels for the heart and lungs are linked to a lower mortality from cancer in men.
3.
A garden can save your life
4.
Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study
5.
Lentiviral Gene Therapy Shows Promise in Severe Hemophilia A
1.
Cancer Vaccines In India: The Latest Hope In The Fight Against Disease
2.
Targeted Approaches to Breast Cancer Liver Metastases: Surgery, Ablation, and Survival Insights
3.
Next-Gen CAR Cell Therapies in Oncology: Frontiers in Solid Tumors & Hematologic Malignancies
4.
The Oncologist’s Edge: Tools, Trials, and Tech Transforming Treatment
5.
Tumor Evolution: Signaling, Plasticity, and Intratumor Heterogeneity in Cancer
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
2.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
4.
CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion
5.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation